secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2022-01-06T23:59:59+00:00
Accession:  0000914121-22-000084
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics Q2 revenue +7.6% to $78.3M; adj. loss per share $0.02; guidance cut on margin and EPS
--------------------------------------------------------------------------------

- Net sales $78.3M (+7.6% YoY); Med Tech +36.4% driven by atherectomy/thrombectomy.
- GAAP net loss $8.4M (-$0.21/share) vs loss $4.3M (-$0.11) a year ago; adjusted loss per share $0.02.
- Gross margin 51.8%, down 340 bps due to supply chain, labor shortages, raw material/freight costs.
- FY2022 revenue guidance reaffirmed $310-315M; gross margin cut to 52-54% from 55%; adj. EPS guidance to ($0.02)-$0.02.
- Full market release of AlphaVac Thrombectomy device commenced after quarter end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000091412122000084/0000914121-22-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000091412122000084/p57239050-8ki.htm
  HTML page:      https://secwatch.observer/filing/0000914121-22-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer